TXNDC9 and colorectal carcinoma: Finally, to evaluate whether TXNDC9 is a client protein of HSP90, we treated CRC cells with the HSP90 agonist Tamox and the HSP90 inhibitor geldanamycin (GEM) in combination with ICA.